Reports Q4 revenue $566.8M, consensus $563.21M. “Exelixis (EXEL) delivered a strong fourth quarter of 2024, positioning us well to maximize success in 2025. Due to the continued outsized performance of the cabozantinib franchise, we generated net product revenues of $515 million and $1.81 billion in the fourth quarter and full year 2024, respectively. Our current 2025 guidance, which does not include any impact from a potential U.S. regulatory approval for CABOMETYX in advanced neuroendocrine tumors, points to solid growth for the cabozantinib franchise. We’re launch-ready for this important indication ahead of an April 3, 2025 PDUFA target action date for our U.S. regulatory filing,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- EXEL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Exelixis price target raised to $43 from $42 at Truist
- Exelixis upgraded to Overweight from Equal Weight at Morgan Stanley
- Exelixis announces results from expansion cohort of phase 1b/2 STELLAR-001
- Exelixis reports on subgroup analysis of Phase 3 CABINET study